Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalization for COVID-19 (MICHELLE): Dr. Ashwin Subramani, PGY3 Previous Molnupiravir for Oral Treatment of Covid-19 in Non-hospitalized Patients Next Disorders of Thrombosis
